Protecting and Developing Revenue Streams: A Primer for Japanese Pharmaceutical Manufacturers
Please join us for a seminar discussing "Protecting and Developing Revenue Streams: A Primer for Japanese Pharmaceutical Manufacturers."
The seminar will take place from 2:00 pm - 5:00 pm with a reception immediately following from 5:00 pm - 7:00 pm.
The seminar will address critical issues in U.S. patent litigation to protect innovator pharmaceutical products, recent significant experiences in IP protection in China, and important considerations for Japanese pharmaceutical companies in pursuing mergers, acquisitions and joint business ventures.
Our program addresses:
Recent Trends in U.S. Patent LitigationAt-risk launches by generic drug makers, compound patent cases after KSR, inequitable conduct cases and the pitfalls of co-pending patent applications.
Case Study: Protecting IP Rights Infringed in ChinaExamine how a pharmaceutical company should manage an Asia-wide anti-piracy initiative and use litigation or administrative process to protect its intellectual property in a case-study format.
Threshold Concerns in Outbound M&AAn overview of best practices for Japanese companies pursuing acquisitions and joint ventures abroad in the fastest consolidating industries - pharmaceuticals and biotech.
Paul Hastings speakers will include Joe O'Malley and Bruce Wexler, of our pharmaceutical patent litigation practice and counsel to Eisai; Yoshi Takatori, head of litigation in the Tokyo office and Ted Johnson and Kenju Watanabe, M&A partners from the Tokyo office.
We hope you will be able to join us for this exclusive and timely program. The presentation will include time for Q&A and will be followed by a cocktail reception.